X0306 4 2020-05-04 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001557290 Arbuckle Stuart A C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP, Chief Commercial Officer Common Stock 2020-05-04 4 M 0 1553 86.52 A 36732 D Common Stock 2020-05-04 4 S 0 640 259.36 D 36092 D Common Stock 2020-05-04 4 S 0 320 260.32 D 35772 D Common Stock 2020-05-04 4 S 0 240 261.34 D 35532 D Common Stock 2020-05-04 4 S 0 240 262.54 D 35292 D Common Stock 2020-05-04 4 S 0 113 264.89 D 35179 D Common Stock 140 I 401(k) Stock Option (Right to Buy) 86.52 2020-05-04 4 M 0 1553 0.00 D 2027-02-02 Common Stock 1553 4660 D Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $259.36 (range $258.85 to $259.74). Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $260.32 (range $259.93 to $260.89). Open market sales reported on this line occurred at a weighted average price of $261.34 (range $261.01 to $261.73). Open market sales reported on this line occurred at a weighted average price of $262.54 (range $262.25 to $262.92). The option vests in 16 quarterly installments from 02/03/2017. /s/ Sabrina Yohai, Attorney-in-Fact 2020-05-06